Impact of kidney transplantation on the progression of cardiovascular disease.
Kidney transplantation, of all the treatment modalities for end-stage renal disease, affords the greatest potential for prolonged survival and improved quality of life. Great strides in immunosuppressant therapy have improved graft survival and forced clinicians to consider other health-care needs of kidney transplant recipients. Chief among these needs is the prevention and treatment of cardiovascular disease. Cardiovascular disease is the most common cause of death among patients with a working renal allograft. Because therapies for primary and secondary prevention are successful in the general population, transplant clinicians are increasingly focused on preventing or limiting the progression of cardiovascular disease. Initiation of aggressive management of conventional atherosclerotic risk factors and uremia-related risk factors, ideally during the early stages of chronic kidney disease (CKD) or after kidney transplantation, and efforts to delay the progression of kidney disease will hopefully reduce the cardiovascular burden in transplant recipients.
Satyan
Sangeetha
S
Department of Medicine, Division of Nephrology, William Beaumont Hospital, Royal Oak, MI 48073, USA.
Rocher
Leslie L
LL
D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology*; D003920:Diabetes Mellitus / Q000209:etiology; D018450:Disease Progression; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology; D006973:Hypertension / Q000209:etiology; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016030:Kidney Transplantation / Q000009:adverse effects*; D012307:Risk Factors
D007166:Immunosuppressive Agents